Skip to main content

Tian Zhang

Adjunct Associate Professor in the Department of Medicine
Medicine, Medical Oncology
DUMC 103861, Durham, NC 27710
Dept of Medicine, Box 103861, Durham, NC 27710

Current Appointments & Affiliations


Adjunct Associate Professor in the Department of Medicine · 2021 - Present Medicine, Medical Oncology, Medicine

Recent Publications


Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging Correlates

Journal Article Clinical Genitourinary Cancer · February 1, 2026 Background Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging is highly sensitive, enabling detection of disease not visualized on conventional imaging, and leading to a new disease state: PSMA-avid/CT-negative metastatic ... Full text Cite

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

Journal Article Clin Cancer Res · December 4, 2025 BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown limited efficacy in unselected patients with metastatic castration-resistant prostate cancer (mCRPC). However, ICIs are approved for biomarker-defined subsets: microsatellite instability-high (MSI- ... Full text Link to item Cite

Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma.

Journal Article Oncologist · December 1, 2025 Overexpression of human epidermal growth factor receptor 2 (HER2) has been implicated as a molecular driver of numerous solid tumor subtypes. An antibody drug conjugate (ADC) directed to HER2, trastuzumab-deruxtecan, recently gained tumor-agnostic FDA appr ... Full text Link to item Cite
View All Publications

Recent Grants


Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023

Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer

ResearchPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2019 - 2022

Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer

ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2016 - 2022

View All Grants

Education, Training & Certifications


Duke University, School of Medicine · 2019 M.H.S.
Harvard Medical School · 2009 M.D.